Observational studyMedicine2015
Colchicine Significantly Reduces Incident Cancer in Gout Male Patients: A 12-Year Cohort Study.
Observational study in Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06304896 (Colchicine Versus Beta-blockers, Angiotensin-converting Enzyme Inhibitors, and Statins for Prevention of Chemotherapy-Induced Cardiomyopathy), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Colchicine Versus Beta-blockers, Angiotensin-converting Enzyme Inhibitors, and Statins for Prevention of Chemotherapy-Induced Cardiomyopathy
Who cites it
25 citing papers in PubMed, 68 citations in OpenAlex.
- Colchicine in coronary artery and cerebrovascular disease: "Old skin for the new ceremony".World journal of cardiology · 2025Review
- Shared Mechanisms in Cancer and Cardiovascular Disease: S100A8/9 and the NLRP3 Inflammasome: JACC: CardioOncology State-of-the-Art Review.JACC. CardioOncology · 2025Review
- Toxic and Hallucinogenic Plants of Southern Chile of Forensic Interest: A Review.Plants (Basel, Switzerland) · 2025Review
- Atherosclerosis and the Bidirectional Relationship Between Cancer and Cardiovascular Disease: From Bench to Bedside, Part 2 Management.International journal of molecular sciences · 2025Review
- Effect of gout and diabetic kidney disease on renal cancer development in Korea.Clinical kidney journal · 2024Article
- Colchicine-The Divine Medicine against COVID-19.Journal of personalized medicine · 2024Review
- The effect of colchicine on cancer risk in patients with immune-mediated inflammatory diseases: a time-dependent study based on the Taiwan's National Health Insurance Research Database.European journal of medical research · 2024Article
- Atherosclerosis and the Bidirectional Relationship between Cancer and Cardiovascular Disease: From Bench to Bedside-Part 1.International journal of molecular sciences · 2024Review
- The genetic advantage of healthy centenarians: unraveling the central role of NLRP3 in exceptional healthspan.Frontiers in aging · 2024Review
- Article
- Role of motor proteins in human cancers.Saudi journal of biological sciences · 2022Review
- High Prevalence of Hyperuricemia and Associated Factors among Zhuang Adults: A Cross-Sectional Study Based on the Ethnic Minority Population Cohort in the Southwestern China.International journal of environmental research and public health · 2022Article
- Determination of Colchicine in Pharmaceutical Formulations, Traditional Extracts, and Ultrasonication-Based Extracts ofPlants (Basel, Switzerland) · 2022Article
- Immuno-cardio-oncology: Killing two birds with one stone?Frontiers in immunology · 2022Review
- Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis:JACC. CardioOncology · 2021Review
- Immunotherapeutic Strategies in Cancer and Atherosclerosis-Two Sides of the Same Coin.Frontiers in cardiovascular medicine · 2021Review
- Cancer incidence in Behçet's disease.Irish journal of medical science · 2020Article
- Article
- Colchicine: Isolation, LC-MS QTof Screening, and Anticancer Activity Study ofMolecules (Basel, Switzerland) · 2019Article
- Cancer incidence in familial Mediterranean fever patients: a retrospective analysis from central Anatolia.Rheumatology international · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with gout are more likely to develop most cancers than subjects without gout. Colchicine has been used for the treatment and prevention of gouty arthritis and has been reported to have an anticancer effect in vitro. However, to date no study has evaluated the relationship between colchicine use and incident cancers in patients with gout. This study enrolled male patients with gout identified in Taiwan's National Health Insurance Database for the years 1998 to 2011. Each gout patient was matched with 4 male controls by age and by month and year of first diagnosis, and was followed up until 2011. The study excluded those who were diagnosed with diabetes or any type of cancer within the year following enrollment. We calculated hazard ratio (HR), aged-adjusted standardized incidence ratio, and incidence of 1000 person-years analyses to evaluate cancer risk. A total of 24,050 male patients with gout and 76,129 male nongout controls were included. Patients with gout had a higher rate of incident all-cause cancers than controls (6.68% vs 6.43%, P = 0.006). A total of 13,679 patients with gout were defined as having been ever-users of colchicine and 10,371 patients with gout were defined as being never-users of colchicine. Ever-users of colchicine had a significantly lower HR of incident all-cause cancers than never-users of colchicine after adjustment for age (HR = 0.85, 95% CI = 0.77-0.94; P = 0.001). In conclusion, colchicine use was associated with a decreased risk of incident all-cause cancers in male Taiwanese patients with gout.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.